Why ChargePoint Stock Hit A New All-Time Low Today

ChargePoint Holdings Inc (NASDAQ: CHPT) shares are trading lower by 6.3% to $1.86 Tuesday afternoon after UBS analyst Robert Jamieson downgraded the stock from Buy to Neutral and lowered the price target from $9 to $2.25.

ChargePoint Holdings Inc (NASDAQ:CHPT) shares are trading lower by 6.3% to $1.86 Tuesday afternoon after UBS analyst Robert Jamieson downgraded the stock from Buy to Neutral and lowered the price target from $9 to $2.25.

ChargePoint shares have marked new all-time lows throughout November, down 43% since November 15th’s session, after the company reported preliminary third-quarter results and announced a new CEO.

What Happened Earlier In November?

In the third quarter of fiscal year 2024, ChargePoint reported lower-than-expected revenue due to several factors like market pressures, delivery delays, and economic conditions in North America and Europe. Their revenue is anticipated to range between $108 million to $113 million, significantly below the initial forecast of $150 million to $165 million.

The new CEO, Rick Wilmer, plans to enhance operations by adjusting inventory and strengthening the business. Preliminary figures show a revenue decline, non-cash impairment charges affecting gross margins, and adjustments in operating expenses.

ChargePoint says the company’s cash position and credit facilities appear stable, but these results might change as quarter-end financial procedures finalize, potentially leading to significant alterations in the reported numbers.

See Also: Why Tharimmune Stock (THAR) Is Down 70% Today

According to data from Benzinga Pro, CHPT has a 52-week high of $13.65 and a 52-week low of $1.95.

Total
0
Shares
Related Posts
Read More

GSK Announced Jemperli RUBY Phase III Trial Met Primary Endpoint in Planned Interim Analysis in Patients With Primary Advanced or Recurrent Endometrial Cancer

GSK plc (LSE/NYSE: GSK) today announced positive headline results from the planned interim analysis of Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by Jemperli compared to chemotherapy plus placebo followed by placebo in adult patients with primary advanced or recurrent endometria

GSK